Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2025-01-08 Board/Management Inform…
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
General Updates
Board/Management Information Classification · 95% confidence The document is a formal letter addressed to stock exchanges and corporate services departments, referencing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015. It announces a change in the names of the company's step-down wholly owned subsidiaries. There is no financial data, no report attached or referenced, and the content is about a corporate structural update. This fits the category of a Board/Management Information filing, as it relates to changes in the company's subsidiaries, which is a management-level disclosure under regulatory requirements.
2025-01-08 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is an official communication from Glenmark Pharmaceuticals Limited to stock exchanges regarding the acquisition of a 34% stake in O2 Renewable Energy XXIV Private Limited. It includes detailed disclosures pursuant to SEBI regulations about the acquisition, such as the nature of the target entity, consideration, shareholding percentage, and background information. The document is a regulatory announcement about a capital investment and acquisition of shares in another company. It is not a financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) because it provides an update on the company's financing activity and acquisition of securities. The document length (7850 characters) and content confirm it is a substantive announcement rather than a brief notice or certification. Therefore, the appropriate classification is CAP with high confidence.
2024-12-18 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a media release announcing the launch of a new pharmaceutical product by Glenmark Pharmaceuticals Inc., USA. It includes details about the product, market data, and company background. There are no financial statements, regulatory filings, voting results, or management changes. The document is a corporate announcement related to product launch and market activity, not a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-12-16 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a media release announcing clinical data from a Phase 1 study of a drug candidate (ISB 2001) by Ichnos Glenmark Innovation. It is addressed to stock exchanges and regulatory bodies, indicating it is an official announcement. The content focuses on clinical trial results, safety, and efficacy data presented at a scientific meeting (ASH Annual Meeting). There are no financial statements, management discussion, or regulatory certifications. The document is not a full financial report, earnings release, or management report. It is a corporate announcement about clinical trial progress and data presentation, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories like earnings, annual report, or capital update. The document length is over 10,000 characters, so it is not a brief report publication announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-12-10 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the loss of a share certificate and the request for issuance of a duplicate share certificate. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate loss and duplicate issuance. The content is about a shareholder's personal share certificate issue and the company's compliance with regulatory requirements. This is not a financial report, earnings release, or management discussion. It is a regulatory announcement related to share certificates and shareholder records. It does not fit into categories like Director's Dealing or Major Shareholding Notification since it concerns a lost certificate and duplicate issuance, not share transactions or ownership changes. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-11-27 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a media release announcing the launch of a new pharmaceutical product by Glenmark Pharmaceuticals Inc., USA. It is addressed to stock exchanges and includes a request to take the announcement on record. The content focuses on product launch details, market data, and company information. There are no financial statements, regulatory filings, or detailed financial performance data. The document is short (4895 characters) and serves as a corporate announcement rather than a financial report or regulatory filing. Therefore, it fits best under the category of a general regulatory announcement or compliance communication rather than a specific financial or management report.
2024-11-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.